Better Health for All

Lexaria Bioscience Corp.'s core DehydraTECH technology consistently demonstrates substantial positive health impacts. Human studies show a 47% reduction in total adverse events and a 54% reduction in gastrointestinal side effects for oral DehydraTECH-processed tirzepatide compared to injectable Zepbound®, with comparable efficacy.

DehydraTECH-processed Rybelsus oral capsules also showed zero adverse events in a human pilot study. In hypertension studies, DehydraTECH-CBD led to statistically significant reductions in 24-hour ambulatory blood pressure (e.g., SBP -4.76 to -5.60 mmHg) over 5 weeks, exceeding levels required to reduce cardiovascular risk, and reduced pro-inflammatory biomarkers by 19-43%. The company has a strong safety record with no serious adverse events reported across multiple human clinical studies involving 134 volunteers. Its clinical trial protocols are randomized, double-blinded, placebo-controlled, and cross-over, with results published in peer-reviewed journals. The company has 39 granted patents globally for its technology and received FDA clearance for a Phase 1b clinical trial for DehydraTECH-CBD in hypertension. The company's business model does not involve products with established negative health outcomes.

Fair Pay & Worker Respect

No specific quantitative data was provided across the articles to assess Lexaria Bioscience Corp. against the defined KPIs for Fair Pay & Worker Respect. Information regarding living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage was not explicitly stated with concrete numbers or outcomes.

While CEO compensation was provided, median employee compensation was not, preventing the calculation of the CEO-median pay ratio. Policies related to safety and reporting violations were mentioned, but no specific incident rates or counts of substantiated violations were given.

Kind to Animals

Lexaria Bioscience Corp. conducts animal testing, including multiple rodent studies.

A 12-week GLP-1, Diabetes Animal Study was mentioned in November 2024, and a 2022 diabetes animal study (DIAB-A22-1) was a multi-week rodent study. The company uses both in vitro and in vivo studies to assess its technology, but the majority of divisions appear to default to animal tests. Its animal testing policy prohibits discretionary testing, but legal mandates still override alternatives. The company operates a licensed in-house research laboratory. There is no evidence of animal agriculture operations or sourcing.

No War, No Weapons

Lexaria Bioscience Corp. is a biotechnology company focused on drug delivery technology, not involved in arms, defense, or military activities.

The company's core business is pharmaceutical research and licensing, which is civilian in nature. There is no evidence of revenue from arms or defense contracts, nor any R&D investment in dual-use technologies with military applications. The company does not engage in sales to embargoed regimes, and its board does not oversee defense-related business. Lexaria explicitly states it does not currently employ AI in its business management or conduct, and therefore has no specific board AI-related risk oversight formalized. The company has no exposure to controversial weapons, no war-risk audits, and no conflict-linked partners. There is no indication of procurement from conflict-affected areas or the use of conflict minerals. The company has a Code of Ethics and an Employee Handbook with a code of conduct, but no specific ethical red lines related to weapons are needed given its business model. The company is not subject to the Arms Trade Treaty, and there is no evidence of exports requiring end-user certificates or procurement activities that would necessitate humanitarian compliance standards.